T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on tough lymphoma shows promise in early trial
Disease control OngoingThis phase 2 study tests whether combining the drug acalabrutinib with a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) can help people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 28 adults will receive the combination. T…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC